Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

Copper (I)-catalyzed 1, 3-dipolar cycloaddition between organic azides and terminal
alkynes, commonly known as CuAAC or click chemistry, has been identified as one of the …

The predictable nature of DNA interactions enables the programmable assembly of highly
advanced 2D and 3D DNA structures of nanoscale dimensions. The access to ever larger …

Beyond traditional needs of biosensors such as high sensitivity and selectivity for analyte
detection, newly emerging requirements including a real-time detection ability and in-field …

Soon after they were first described in 1990, aptamers were largely recognized as a new
class of biological ligands that can rival antibodies in various analytical, diagnostic, and …

Rapid progress in identifying biomarkers that are hallmarks of disease has increased
demand for high-performance detection technologies. Implementation of electrochemical …

The oligonucleotide therapeutics field has seen remarkable progress over the last few years
with the approval of the first antisense drug and with promising developments in late stage …

Cu (I)-catalyzed azide–alkyne 1, 3-dipolar cycloaddition (CuAAC), popularly known as the
“click reaction”, serves as the most potent and highly dependable tool for facile construction …

Functional nucleic acid (NA)-based drugs have a broad range of applications since they
allow the alteration and control of gene/protein expression patterns in cells. In principle …

Oligonucleotides (ONs) can interfere with biomolecules representing the entire extended
central dogma. Antisense gapmer, steric block, splice-switching ONs, and short interfering …